REFERENCES
1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
2. Mauro E, de Castro T, Zeitlhoefler M, et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 2025;7:101571.
3. Ohtani N, Kamiya T, Kawada N. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond. Hepatol Commun. 2023;7:e0241.
5. Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien PA. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol. 2020;17:755-72.
6. Yilma M, Houhong Xu R, Saxena V, et al. Survival outcomes among patients with hepatocellular carcinoma in a large integrated US health system. JAMA Netw Open. 2024;7:e2435066.
7. Lim RY, Koh B, Ng CH, et al. ; Liver Cancer Research Network. Hepatocellular carcinoma surveillance and survival in a contemporary Asia-Pacific cohort. JAMA Netw Open. 2025;8:e2520294.
8. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864-84.
9. Su X, Yan X, Zhang H. The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine. Mol Cancer. 2025;24:173.
10. Franzè MS, Saffioti F, Mavroeidis VK. Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC. Cancer Drug Resist. 2025;8:33.
11. Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368:973-80.
12. Huang JH, Wang J, Chai XQ, et al. The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma. Microbiol Spectr. 2022;10:e0098322.
13. Liu B, Zhou Z, Jin Y, et al. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma. J Immunother Cancer. 2022;10:e003069.
14. He Y, Zhang Q, Yu X, Zhang S, Guo W. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J Transl Med. 2023;21:68.
15. Wang X, Fang Y, Liang W, et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice. Nat Microbiol. 2025;10:169-84.
16. Lu Y, Xu L, Chen W, et al. Intrahepatic microbial heterogeneity in multifocal hepatocellular carcinoma and its association with host genomic and transcriptomic alterations. Cancer Discov. 2025;15:1630-48.
17. Jiang F, Dang Y, Zhang Z, et al. Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis. mSystems. 2025;10:e0076524.
19. Giraud J, Saleh M. Host-microbiota interactions in liver inflammation and cancer. Cancers. 2021;13:4342.
20. Jiang N, Xiao Y, Yuan K, Wang Z. Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites. J Gastroenterol Hepatol. 2023;38:1056-71.
21. An L, Wirth U, Koch D, et al. The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases. J Gastrointest Surg. 2022;26:671-83.
22. Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal barrier function-non-alcoholic fatty liver disease interactions and possible role of gut microbiota. J Agric Food Chem. 2019;67:2754-62.
23. Feng D, Zhang H, Jiang X, et al. Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice. Environ Pollut. 2020;265:114880.
24. Ming Z, Ruishi X, Linyi X, Yonggang Y, Haoming L, Xintian L. The gut-liver axis in fatty liver disease: role played by natural products. Front Pharmacol. 2024;15:1365294.
25. Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830-4.
26. Bertocchi A, Carloni S, Ravenda PS, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021;39:708-24.e11.
27. Liu N, Wang X, Steer CJ, Song G. MicroRNA-206 promotes the recruitment of CD8+ T cells by driving M1 polarisation of Kupffer cells. Gut. 2022;71:1642-55.
29. Jain H, Kumar A, Almousa S, et al. Characterisation of LPS+ bacterial extracellular vesicles along the gut-hepatic portal vein-liver axis. J Extracell Vesicles. 2024;13:e12474.
30. Elvevi A, Laffusa A, Gallo C, Invernizzi P, Massironi S. Any role for microbiota in cholangiocarcinoma? A comprehensive review. Cells. 2023;12:370.
31. Schulz C, Vilchez-Vargas R, Öcal E, et al. Profiling of the tumor-associated microbiome in patients with hepatocellular carcinoma. Gut Pathog. 2025;17:53.
32. Tsuei J, Chau T, Mills D, Wan YJ. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med. 2014;239:1489-504.
33. Li J, Zhai X, Chen C, Zhang R, Huang X, Liu Y. The intrahepatic bacterial metataxonomic signature of patients with hepatocellular carcinoma. Sci Rep. 2024;14:29077.
34. Ren X, Zheng G, Liu Y, et al. Intratumoral bacterium Enterocloster bolteae promotes hepatocellular carcinoma progression by directly binding tumor cells. Cell Host Microbe. 2026;34:406-24.e10.
35. Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov. 2017;7:522-38.
36. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97-101.
37. Pan D, Bao Y, Lu X, Gu Q, Zhang Y, Zheng Y. Short-chain fatty acids regulate hepatocellular carcinoma progression: a metabolic perspective on tumor immunity (Review). Int J Mol Med. 2025;56:214.
38. Wu L, Feng J, Li J, et al. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother. 2021;133:111036.
39. Che Z, Xue W, Zhao X, Hu C, Tian Y. Regulatory role and biomarker potential of gut microbiota metabolites in the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma. Clin Transl Gastroenterol. 2025;16:e00914.
40. Wang J, Jiang R. Targeting gut microbiota to overcome immunotherapy resistance in hepatocellular carcinoma: from mechanisms to clinical practice. Hepatoma Res. 2026;12:25.
41. Sun L, Ke X, Guan A, et al. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery. Clin Transl Med. 2023;13:e1331.
42. Li S, Xia H, Wang Z, et al. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC. Hepatology. 2023;78:1079-91.
43. Yang J, He Q, Lu F, et al. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma. Gut Microbes. 2023;15:2201159.
44. Lin H, Ma Z, Li J, et al. Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma. Front Immunol. 2024;15:1500863.
45. Chen Q, Wang Y, Wu D, Zhang H, Xia Q, Qu D. Integrated microbiome-metabolome profiling unveils a predictive signature for early recurrence in hepatocellular carcinoma. Front Microbiol. 2025;16:1653249.
46. Liu Q, Wang J, Yao Y, et al. Intratumor Rhodococcus sp. B513 drives DEN-induced hepatocellular carcinoma progression by modulating gut microbiota and angiogenesis. Curr Res Microb Sci. 2025;9:100428.
47. Li L, Wang M, Jiang Z, Yi C, Yi Y. Intratumoral microbial heterogeneity in HCC reveals a potential therapeutic target. JHEP Rep. 2025;7:101538.
48. Huang H, Ren Z, Gao X, et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med. 2020;12:102.
49. Liu Y, Kim ES, Guo H. Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures. J Med Virol. 2024;96:e29485.
50. Dang Y, Huang J, Peng X, Wang Y, Wang J. Identification of intratumoral bacteria correlated with hepatitis B virus (HBV) levels: a prognostic indicator for patient outcomes in hepatocellular carcinoma patients. Microbiol Spectr. 2025;13:e0118825.
51. Liu Q, Liu Y, Zhou Y, et al. Intratumoral Lactobacillus johnsonii enhances sensitivity to PD-1 blockade by inducing CD8+ T-cell expansion in hepatocellular carcinoma. Cancer Res. 2026;86:1939-55.
52. Zhang Y, Liu W, Wong CC, et al. Catenibacteriummitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid. Cell Metab. 2025;37:1998-2013.e7.
53. Magdy Wasfy R, Abdoulaye A, Borentain P, et al. Thomasclavelia ramosa and alcohol-related hepatocellular carcinoma: a microbial culturomics study. Gut Pathog. 2025;17:27.
54. Shen W, Li Z, Wang L, et al. Tumor-resident Malassezia can promote hepatocellular carcinoma development by downregulating bile acid synthesis and modulating tumor microenvironment. Sci Rep. 2025;15:15020.
55. Zheng J, Wang S, Xia L, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10:35.
56. Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8:35.
57. Zhang H, Fu L, Leiliang X, et al. Beyond the gut: the intratumoral microbiome’s influence on tumorigenesis and treatment response. Cancer Commun. 2024;44:1130-67.
58. Schorr L, Mathies M, Elinav E, Puschhof J. Intracellular bacteria in cancer-prospects and debates. NPJ Biofilms Microbiomes. 2023;9:76.
59. Fu Y, Li J, Cai W, et al. The emerging tumor microbe microenvironment: from delineation to multidisciplinary approach-based interventions. Acta Pharm Sin B. 2024;14:1560-91.
60. Kwon SY, Thi-Thu Ngo H, Son J, Hong Y, Min JJ. Exploiting bacteria for cancer immunotherapy. Nat Rev Clin Oncol. 2024;21:569-89.
61. Baruch EN, Wang J, Wargo JA. Gut microbiota and antitumor immunity: potential mechanisms for clinical effect. Cancer Immunol Res. 2021;9:365-70.
62. Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371:eabc4552.
63. Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360:eaan5931.
64. Wu XQ, Ying F, Chung KPS, et al. Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. Cell Rep Med. 2025;6:101900.
65. Pan B, Zhang X, Ye D, et al. Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma. Cell Death Dis. 2025;16:407.
66. Fu Y, Bonifacio-Mundaca J, Desterke C, Casafont Í, Mata-Garrido J. Genomic alterations and microbiota crosstalk in hepatic cancers: the gut-liver axis in tumorigenesis and therapy. Genes. 2025;16:920.
67. Ji S, Liu Y, Xu Y, et al. Faecalibacterium prausnitzii enzyme reprograms PD-L1 trafficking and sensitizes colorectal cancer to immunotherapy in mice. Nat Microbiol. 2026;11:1318-35.
68. Li B, Liu G, Zhu Y, et al. Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy. Cell Host Microbe. 2026;34:657-71.e7.
69. Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.
70. Chen W, Zhang X, Chi M, Zheng Q. Intratumoral microbe correlated with expression of DNA methylation genes in hepatocellular carcinoma. Dig Dis Sci. 2025;70:3383-93.
71. Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-23.
72. Jo HE, Khom S, Lee S, et al. Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues. Sci Rep. 2024;14:26092.
73. Zhao R, Li J, Chen B, et al. The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma. Front Immunol. 2023;14:1289753.
74. Yu H, Lin G, Jiang J, et al. Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib. Gut Microbes. 2024;16:2410474.
75. Al-Akayleh F, Agha ASAA, Al-Remawi M, et al. What we know about the actual role of traditional probiotics in health and disease. Probiotics Antimicrob Proteins. 2024;16:1836-56.
76. Bubnov RV, Spivak MY, Lazarenko LM, Bomba A, Boyko NV. Probiotics and immunity: provisional role for personalized diets and disease prevention. EPMA J. 2015;6:14.
77. Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr. 2018;7:11-20.
78. Llamoza-torres CJ, Fuentes-pardo M, Ramos-molina B. Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response. Metab Target Organ Damage. 2024;4:40.
79. Kalligeros M, Henry LL, Younossi ZM. Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights. Metab Target Organ Damage. 2025;5:31.
80. Lau HC, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid. EBioMedicine. 2024;100:104952.
81. Song Q, Zhang X, Liu W, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79:1352-65.
82. Chen P, Yang C, Ren K, et al. Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma. Front Immunol. 2024;15:1504948.
83. Si W, Liang H, Bugno J, et al. Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71:521-33.
84. Bajaj JS, Salzman N, Acharya C, et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. JCI Insight. 2019;4:133410.
85. Lamas-Paz A, Mesquita M, Garcia-Lacarte M, et al. Fecal microbiota transplantation from female donors restores gut permeability and reduces liver injury and inflammation in middle-aged male mice exposed to alcohol. Front Nutr. 2024;11:1393014.
86. Rauber C, Roberti MP, Vehreschild MJ, et al. Protocol: faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). BMJ Open. 2025;15:e097802.
87. Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol. 2022;37:7-14.
88. Hao M, Wang Z, Wang L, et al. Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD. Front Pharmacol. 2025;16:1657751.
89. Wu XQ, Lee TKW. Influence of the gut microbiota on the response to immunotherapy in hepatocellular carcinoma. Hepatoma Res 2025;11:16.
90. Ma C, Awosika JA, Monge C, et al. Altering the gut microbiome and tumor microenvironment in advanced liver cancer: a phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers. Cancer Lett. 2025;632:217975.
91. Schneider KM, Mohs A, Gui W, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun. 2022;13:3964.
92. Singh V, Yeoh BS, Abokor AA, et al. Vancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota. Gut Microbes. 2020;11:1077-91.
93. Hu J, Ran S, Huang Z, et al. Antibacterial tellurium-containing polycarbonate drug carriers to eliminate intratumor bacteria for synergetic chemotherapy against colorectal cancer. Acta Biomater. 2024;185:323-35.
94. Qiu Q, Lu D, Liu G, et al. Colistin crosslinked gemcitabine micelles to eliminate tumor drug resistance caused by intratumoral microorganisms. Bioconjug Chem. 2022;33:1944-52.
95. Yao H, Ma S, Huang J, et al. Trojan-horse strategy targeting the gut-liver axis modulates gut microbiome and reshapes microenvironment for orthotopic hepatocellular carcinoma therapy. Adv Sci. 2024;11:e2310002.
96. Rothong P, Leungtongkam U, Khongfak S, et al. Antimicrobial activity and synergistic effect of phage-encoded antimicrobial peptides with colistin and outer membrane permeabilizing agents against Acinetobacter baumannii. PeerJ. 2024;12:e18722.
97. Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: from biological mechanisms to future directions. Cell. 2023;186:17-31.
98. Olawade DB, Fapohunda O, Egbon E, et al. Phage therapy: a targeted approach to overcoming antibiotic resistance. Microb Pathog. 2024;197:107088.
99. Ding X, Ting NL, Wong CC, et al. Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe. 2025;33:941-56.e10.
